GC LabTech, Inc. (GCLT, San Antonio, TX, USA) closed out a successful 2024! Poised for more growth in 2025, GCLT has selected the recently US-FDA Approved Donor Screening Serology Platform from Roche Diagnostics. GCLT will soon begin transitioning its Viral Marker Testing from the Quidel Ortho Verseia Integrated Platform to the Roche Diagnostics Cobas® Pro Serology Solution. The addition of the Roche Serology Platform will further strengthen GCLT’s relationship with Roche Diagnostics, which also provides the Nucleic Acid Testing platform required for plasma donor screening.
In 2024, Quidel Ortho announced a Phased-Out departure from Donor Testing.